Sarah Kathryn Rouan

CIK: 0001761366

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)1 (20.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VKTX

Viking Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VKTX
Viking Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
3.2K shares-
VKTX
Viking Therapeutics, Inc.
Mar 31, 2025
Purchase(P)
Direct
1.2K shares at avg. $24.15$30K
VKTX
Viking Therapeutics, Inc.
Jan 2, 2025
Award(A)
Stock Option (Right to Buy)
Direct
18.8K shares-
VKTX
Viking Therapeutics, Inc.
Oct 25, 2024
Exercise(M)
Direct
11K shares at avg. $4.88$54K
VKTX
Viking Therapeutics, Inc.
Oct 25, 2024
Sale(S)
Direct
11K shares at avg. $80.89$890K

		Type	Shares	Price		Ownership
Jan 2, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	3,150	-	$0	Direct
Mar 31, 2025	VKTX Viking Therapeutics, Inc.	Purchase(P)	1,240	$24.15	$29,943	Direct
Jan 2, 2025	VKTX Viking Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	18,800	-	-	Direct
Oct 25, 2024	VKTX Viking Therapeutics, Inc.	Exercise(M)	11,000	$4.88	$53,680	Direct
Oct 25, 2024	VKTX Viking Therapeutics, Inc.	Sale(S)	11,000	$80.89	$889,790	Direct

1-5 of 5 transactions

About Rouan Sarah Kathryn

Rouan Sarah Kathryn (SEC CIK 0001761366) files insider reports with the SEC as Director of Viking Therapeutics, Inc. (VKTX).

Signal8 holds 5 ownership filings by Rouan Sarah Kathryn, all Form 4s, filed between Oct 25, 2024 and Jan 5, 2026. Those filings report 5 transactions, from Oct 25, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rouan Sarah Kathryn's filings is in SAN DIEGO, CA.

Recent filings by Rouan Sarah Kathryn

Jan 2, 2026: Grant or award of VKTX shares (Form 4, code A).
Mar 31, 2025: Open-market purchase of VKTX shares (Form 4, code P).
Jan 2, 2025: Grant or award of VKTX derivative securities (Form 4, code A).
Oct 25, 2024: Option exercise of VKTX shares (Form 4, code M).
Oct 25, 2024: Open-market sale of VKTX shares (Form 4, code S).

Other insiders filing for Viking Therapeutics, Inc. (VKTX)

Kelly-Gemmell Dorothy Elizabeth, Director
Lian Brian, President & CEO
ZANTE GREG, Chief Financial Officer
Mancini Marianna, Chief Operating Officer
Chen Hubert C, Chief Medical Officer
Aubuchon Neil William, Chief Commercial Officer

How to read Form 4 transaction codes